Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1865 million
Deal Type : Collaboration
Repertoire® and Bristol Myers Squibb Collaborate On Tolerizing Vaccines
Details : In collaboration, Repertoire leads candidate development while BMS commercializes tolerizing vaccines under an exclusive license for treating type 1 diabetes.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : $65.0 million
April 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1865 million
Deal Type : Collaboration
Details : RPTR-168 is designed to deliver interleukin-12 (IL-12), a potent immunomodulatory agent that has been shown to improve anti-tumor activity by promoting T cell function inside the tumor microenvironment.
Brand Name : RPTR-168
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 10, 2022
Details : Repertoire’s DECODE platform is a suite of integrated experimental and computational technologies designed to decipher the immune synapse, the complex interface between T cells and the epitopes they recognize, which are presented on antigen-presenting ...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 05, 2022
Lead Product(s) : RPTR-168
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Repertoire’s proprietary cell-tethering technology RPTR-168 limits systemic toxicity typically associated with use of immunomodulatory IL-12 and allows direct delivery to solid tumors in mouse models.
Brand Name : RPTR-168
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : RPTR-168
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RPTR-147
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRIME IL-15 is a novel non-genetically modified, autologous, multiclonal T cell product derived from the patient’s T cell repertoire in the peripheral blood, activated against a curated set of tumor antigens, and armored with an IL-15Fc nanogel.
Brand Name : PRIME IL-15
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 09, 2021
Lead Product(s) : RPTR-147
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Research demonstrates the ability of DECODE™ platform to identify T cell receptors and their cognate antigens critical for the understanding of long-term immunity against infectious agents such as SARS-CoV-2.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRIME IL-15 cell therapy
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Clinical biomarker data also provided evidence of PRIME IL-15 biological activity. Persistence of T cell clones derived from RPTR-147 was observed in both the blood and within the tumor.
Brand Name : RPTR-147
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 09, 2020
Lead Product(s) : PRIME IL-15 cell therapy
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : JDRF T1D
Deal Size : Undisclosed
Deal Type : Financing
Details : The investment from the JDRF T1D Fund wil help company to utilize its core platforms to discover new antigens and T cell receptors in hopes of advancing the development of treatments for T1D.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : JDRF T1D
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?